FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Third-Party Review Guidance Explained

[ Price : $8.95]

CDRH policy analyst Allen Hill explains the voluntary 510(k) third-party review program in a Webinar presentation.

Individualized Therapeutics Workshop Transcript Out

[ Price : $8.95]

CBER releases the transcript from a 3/3 public workshop on individualized therapeutics regulated by the Center.

Refusal-to-File letter on BMS/Bluebird BLA

[ Price : $8.95]

FDA issues a refusal to file letter to Bristol Myers Squibb and Bluebird Bio for a BLA for idecabtagene vicleucel, indicated for t...

MasterPharm Recalls Finasteride Due to High Drug Levels

[ Price : $8.95]

MasterPharm recalls one lot of finasteride plus 1.25mg capsules because they were found to contain higher levels of minoxidil, an ...

Lack of Evidence for Compounded Pain Creams: Report

[ Price : $8.95]

A National Academies report finds no evidence to support the safety or effectiveness of compounded topical pain creams.

Compounded Drug MOU Out for Viewing

[ Price : $8.95]

FDA releases for public viewing a memorandum of understanding between the agency and states on regulation of drug compounding.

Vanda, FDA Agree to Hetlioz Submissions

[ Price : $8.95]

Vanda Pharmaceuticals says it has reached agreement with FDA to resubmit an NDA and supplemental NDA for Hetlioz (tasimelteon) for...

Philips Ultrasound Options Cleared for Covid-19

[ Price : $8.95]

FDA clears a Royal Philips 510(k) for ultrasound options for managing Covid-19-related lung and cardiac complications.

FDA Updates Covid Clinical Trial Guidance

[ Price : $8.95]

FDA says it has updated the question-and-answer appendix in its guidance on conducting medical product clinical trials during the ...

CDER Recommendations on IND Inquiries for Covid Drugs

[ Price : $8.95]

CDER outlines recommendations for drug sponsors seeking product development inquiries for Covid-19 products.